116 related articles for article (PubMed ID: 22705639)
1. Uricase from Bacillus fastidious loaded in alkaline enzymosomes: enhanced biochemical and pharmacological characteristics in hypouricemic rats.
Tan Q; Zhang J; Wang N; Li X; Xiong H; Teng Y; He D; Wu J; Zhao C; Yin H; Zhang L
Eur J Pharm Biopharm; 2012 Sep; 82(1):43-8. PubMed ID: 22705639
[TBL] [Abstract][Full Text] [Related]
2. A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
Feng J; Li X; Yang X; Zhang C; Yuan Y; Pu J; Zhao Y; Xie Y; Yuan H; Bu Y; Liao F
Arch Pharm Res; 2010 Nov; 33(11):1761-9. PubMed ID: 21116779
[TBL] [Abstract][Full Text] [Related]
3. Improved biological properties and hypouricemic effects of uricase from Candida utilis loaded in novel alkaline enzymosomes.
Tan QY; Zhang JQ; Wang N; Yang H; Li X; Xiong HR; Wu JY; Zhao CJ; Wang H; Yin HF
Int J Nanomedicine; 2012; 7():3929-38. PubMed ID: 22915844
[TBL] [Abstract][Full Text] [Related]
4. [The Pharmacokinetics and Pharmacodynamics of Intravenous Uricase Multivesicular Liposomes].
Deng X; He D; Xiong HR; Zhou YL; Zhang JQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 46(5):688-91. PubMed ID: 26619536
[TBL] [Abstract][Full Text] [Related]
5. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a uricase from Bacillus fastidious A.T.C.C. 26904 and its application to serum uric acid assay by a patented kinetic uricase method.
Zhao Y; Zhao L; Yang G; Tao J; Bu Y; Liao F
Biotechnol Appl Biochem; 2006 Sep; 45(Pt 2):75-80. PubMed ID: 16689679
[TBL] [Abstract][Full Text] [Related]
7. Use of the uricase-inhibited rat as an animal model in toxicology.
Stavric B; Nera EA
Clin Toxicol; 1978; 13(1):47-74. PubMed ID: 367691
[TBL] [Abstract][Full Text] [Related]
8. Nanosomal Microassemblies for Highly Efficient and Safe Delivery of Therapeutic Enzymes.
Xiong H; Zhou Y; Zhou Q; He D; Wan S; Tan Q; Zhang M; Deng X; Zhang J
ACS Appl Mater Interfaces; 2015 Sep; 7(36):20255-63. PubMed ID: 26325262
[TBL] [Abstract][Full Text] [Related]
9. Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
Zhang C; Fan K; Luo H; Ma X; Liu R; Yang L; Hu C; Chen Z; Min Z; Wei D
Int J Pharm; 2012 Jul; 430(1-2):307-17. PubMed ID: 22503989
[TBL] [Abstract][Full Text] [Related]
10. Comparison of modification of a bacterial uricase with N-hydroxysuccinimide esters of succinate and carbonate of monomethoxyl poly(ethylene glycol).
Zhang C; Yang X; Gao A; Hu X; Pu J; Liu H; Feng J; Liao J; Li Y; Liao F
Biotechnol Appl Biochem; 2014; 61(6):683-90. PubMed ID: 24512141
[TBL] [Abstract][Full Text] [Related]
11. Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase.
Abuchowski A; Karp D; Davis FF
J Pharmacol Exp Ther; 1981 Nov; 219(2):352-4. PubMed ID: 7288624
[TBL] [Abstract][Full Text] [Related]
12. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
Sherman MR; Saifer MG; Perez-Ruiz F
Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
[TBL] [Abstract][Full Text] [Related]
13. Uricase alkaline enzymosomes with enhanced stabilities and anti-hyperuricemia effects induced by favorable microenvironmental changes.
Zhou Y; Zhang M; He D; Hu X; Xiong H; Wu J; Zhu B; Zhang J
Sci Rep; 2016 Jan; 7():20136. PubMed ID: 26823332
[TBL] [Abstract][Full Text] [Related]
14. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
Horiuchi H; Ota M; Kobayashi M; Kaneko H; Kasahara Y; Nishimura S; Kondo S; Komoriya K
Res Commun Mol Pathol Pharmacol; 1999; 104(3):307-19. PubMed ID: 10741381
[TBL] [Abstract][Full Text] [Related]
15. Nanocapsule assemblies as effective enzyme delivery systems against hyperuricemia.
Xiong H; Zhou Y; Zhou Q; He D; Deng X; Sun Q; Zhang J
Nanomedicine; 2016 Aug; 12(6):1557-66. PubMed ID: 27013130
[TBL] [Abstract][Full Text] [Related]
16. Production of a thermostable uricase by a novel Bacillus thermocatenulatus strain.
Lotfy WA
Bioresour Technol; 2008 Mar; 99(4):699-702. PubMed ID: 17395458
[TBL] [Abstract][Full Text] [Related]
17. An amperomertic uric acid biosensor based on immobilization of uricase onto polyaniline-multiwalled carbon nanotube composite film.
Bhambi M; Sumana G; Malhotra BD; Pundir CS
Artif Cells Blood Substit Immobil Biotechnol; 2010 Aug; 38(4):178-85. PubMed ID: 20367113
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man.
Yamada I; Fukunari A; Osajima T; Kamezawa M; Mori H; Iwane J
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1123-5. PubMed ID: 15571214
[TBL] [Abstract][Full Text] [Related]
20. Effects of modification of amino groups with poly(ethylene glycol) on a recombinant uricase from Bacillus fastidiosus.
Zhang C; Yang X; Feng J; Yuan Y; Li X; Bu Y; Xie Y; Yuan H; Liao F
Biosci Biotechnol Biochem; 2010; 74(6):1298-301. PubMed ID: 20530883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
